N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
-
Stefanie Albers
Abstract
The aim of the present study was the investigation of N-terminal pro-brain natriuretic peptide (NT-proBNP) in the pediatric population. This is essential for adequate monitoring and classification of pediatric patients with heart disease, but no consistent data are available yet. In addition, the comparability of two commercially available NT-proBNP assays and the inter-laboratory variability for the most suitable one were assessed. For this purpose, 408 subjects (1–29years) were included. NT-proBNP was determined with a non-competitive electrochemiluminescent immunoassay (Roche NT-proBNP; n=402) and a competitive enzyme-immunoassay (Biomedica NT-proBNP; n=402). Inter-laboratory variability was evaluated for the Roche assay by stepwise inclusion of four and 11 centers throughout Germany, respectively. Roche NT-proBNP ranged from 5.0 to 391.5ng/L, with higher values for younger children. The 97.5th (75th) percentile curve ranged from 319.9ng/L (231.2 ng/L, 1–3years) to 114.9ng/L (53.3 ng/L, 18years). In contrast, Biomedica NT-proBNP ranged from 253.7 to 7602.8 ng/L, with no significant age dependency. The mean difference between the assays was 1649.7ng/L (95% confidence interval 1546.3–1753.1ng/L). Inter-laboratory variability ranged from 6.5% to 3.8%, covering a range from 51.3 to 6618.1ng/L. The assay seems to influence the interpretation of resulting NT-proBNP values and therefore has to be chosen carefully. For the monitoring and classification of pediatric patients with congenital heart disease, age-based NT-proBNP values should be used.
References
1. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50:33–50.10.1373/clinchem.2003.024760Suche in Google Scholar
2. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004; 164:1978–84.10.1001/archinte.164.18.1978Suche in Google Scholar
3. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005; 330:625.10.1136/bmj.330.7492.625Suche in Google Scholar
4. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126–30.10.1016/S0140-6736(00)02060-2Suche in Google Scholar
5. Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004; 6:261–8.10.1016/j.ejheart.2004.01.004Suche in Google Scholar PubMed
6. Collinson PO, Barnes SC, Gaze DC, Galasko G, Lahiri A, Senior R. Analytical performance of the N-terminal pro B-type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004; 6:365–8.10.1016/j.ejheart.2004.01.011Suche in Google Scholar PubMed
7. Mueller T, Gegenhuber A, Dieplinger B, Poelz W, Haltmayer M. Long-term stability of endogenous B-type natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP) in frozen plasma samples. Clin Chem Lab Med 2004; 42:942–4.10.1515/CCLM.2004.153Suche in Google Scholar PubMed
8. Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38:519–23.10.1515/CCLM.2000.076Suche in Google Scholar PubMed
9. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) 1997; 47:287–96.10.1046/j.1365-2265.1997.2361058.xSuche in Google Scholar PubMed
10. Tulevski , II, Groenink M, van Der Wall EE, van Veldhuisen DJ, Boomsma F, Stoker J, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001; 86:27–30.Suche in Google Scholar
11. Book WM, Hott BJ, McConnell M. B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am J Cardiol 2005; 95:545–6.10.1016/j.amjcard.2004.10.031Suche in Google Scholar PubMed
12. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002; 106:92–9.10.1161/01.CIR.0000020009.30736.3FSuche in Google Scholar
13. Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 2004; 109:2872–7.10.1161/01.CIR.0000129305.25115.80Suche in Google Scholar
14. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350:655–63.10.1056/NEJMoa031994Suche in Google Scholar
15. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89:745–51.10.1136/heart.89.7.745Suche in Google Scholar
16. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5:599–606.10.1016/S1388-9842(03)00108-9Suche in Google Scholar
17. Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 2002; 110:e76.10.1542/peds.110.6.e76Suche in Google Scholar PubMed
18. Mir TS, Laux R, Hellwege HH, Liedke B, Heinze C, von Buelow H, et al. Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Pediatrics 2003; 112:896–9.10.1542/peds.112.4.896Suche in Google Scholar PubMed
19. Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 2004; 93:603–7.10.1111/j.1651-2227.2004.tb02984.xSuche in Google Scholar PubMed
20. Rauh M, Koch A. Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Clin Chem 2003; 49:1563–4.10.1373/49.9.1563Suche in Google Scholar PubMed
21. Schwachtgen L, Herrmann M, Georg T, Schwarz P, Marx N, Lindinger A. Reference values of NT-proBNP serum concentrations in the umbilical cord blood and in healthy neonates and children. Z Kardiol 2005; 94:399–404.10.1007/s00392-005-0246-xSuche in Google Scholar PubMed
22. Clerico A, Del Ry S, Giannessi D. Measurement of cardiac natriuretic hormones (atrial natriuretic peptide, brain natriuretic peptide, and related peptides) in clinical practice: the need for a new generation of immunoassay methods. Clin Chem 2000; 46:1529–34.10.1093/clinchem/46.10.1529Suche in Google Scholar
23. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003; 49:976–9.10.1373/49.6.976Suche in Google Scholar PubMed
24. Hammerer-Lercher A, Ludwig W, Falkensammer G, Muller S, Neubauer E, Puschendorf B, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 2004; 50:1174–83.10.1373/clinchem.2003.028316Suche in Google Scholar PubMed
25. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004; 42:965–72.10.1515/CCLM.2004.157Suche in Google Scholar PubMed
26. Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J, et al. Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender. Pediatr Cardiol 2005. In press. (DOI: 10.1007/s00246-005-1022-4).Suche in Google Scholar
27. Biomedica Group. Assay specification, 2004.Suche in Google Scholar
28. Roche Diagnostics. Assay specifications, 2002.Suche in Google Scholar
29. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999; 8:135–60.10.1177/096228029900800204Suche in Google Scholar PubMed
30. Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003; 89:875–8.10.1136/heart.89.8.875Suche in Google Scholar PubMed PubMed Central
31. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6:257–60.10.1016/j.ejheart.2003.12.015Suche in Google Scholar PubMed
32. Shih HC, Chao L, Chao J. Age and hormonal dependence of tonin levels in rat submandibular gland as determined by a new direct radioimmunoassay. Biochem J 1986; 238:145–9.10.1042/bj2380145Suche in Google Scholar PubMed PubMed Central
33. Maffei S, Del Ry S, Prontera C, Clerico A. Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci (Lond) 2001; 101:447–53.10.1042/CS20010039Suche in Google Scholar
©2006 by Walter de Gruyter Berlin New York
Artikel in diesem Heft
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
Artikel in diesem Heft
- Where does the evidence come from?
- NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer
- Plasma cell-free DNA as an indicator of severity of injury in burn patients
- Bivariate statistical approach to evaluate laboratory performance by analysis of standard curves in an External Quality Assurance program for quantitative assays based on real-time PCR with Taq-Man™ probes
- Erythrocyte membrane acetylcholinesterase activity in subjects with MTHFR 677C→T genotype
- Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors
- APO A-V–1131T→C polymorphism frequency and its association with morbidity in a Brazilian elderly population
- Association study between fibronectin and coronary heart disease
- Serum calcium and phosphorus associate with the occurrence and severity of angiographically documented coronary heart disease, possibly through correlation with atherogenic (apo)lipoproteins
- Urinary calcium excretion in severe preeclampsia and eclampsia
- In vitro re-mineralization of demineralized bone matrix in human serum
- Measurement of serum amyloid A1 (SAA1), a major isotype of acute phase SAA
- Disturbed lipoprotein composition in non-dialyzed, hemodialysis, continuous ambulatory peritoneal dialysis and post-transplant patients with chronic renal failure
- Measurement of serum testosterone using high-performance liquid chromatography/tandem mass spectrometry
- Quantitative bacterial micro-assay for rapid detection of serum phenylalanine on dry blood-spots: application in phenylketonuria screening
- N-Terminal pro-brain natriuretic peptide: normal ranges in the pediatric population including method comparison and interlaboratory variability
- A new quality control model using performance goals based on biological variation in External Quality Assurance Schemes
- Improvement in glycemic control over 11 years in patients monitored for diabetes in one county
- The clinical usefulness of glucose tolerance testing in gestational diabetes to predict early postpartum diabetes mellitus
- Analytical performance of a new two-step ADVIA Centaur® estradiol immunoassay during ovarian stimulation
- EC4 European Syllabus for Post-Graduate Training in Clinical Chemistry and Laboratory Medicine: version 3 – 2005
- POX-Act assay and d-ROMs test – what are the facts?
- External quality control of urinary methyl malonic acid quantification – announcement of a pilot study
